Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,615
datasets available to search
ShareScore release 0.9.0
Dataset results
2,615 results for “HIV Infections”
Anti-HIV Medications for People Recently Infected With HIV
ClinicalTrials.gov study NCT00106171. IPD Sharing: Not stated. Countries: 2. Publications: 1.
iHIVARNA Clinical Trial in HIV Infected Individuals
ClinicalTrials.gov study NCT02888756. IPD Sharing: Not stated. Countries: 3. Publications: 1.
To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
ClinicalTrials.gov study NCT00959166. IPD Sharing: NO. Countries: 1. Publications: 1.
Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
ClinicalTrials.gov study NCT03702049. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Data from: HIV-1 capsid stability enables inositol phosphate-independent infection of target cells and promotes integration into genes
Open the record for dataset details and reuse information.
A specific IL6 polymorphic genotype modulates the risk of T. cruzi parasitemia while IL18, IL17A and IL1B variant profiles and HIV infection protect against cardiomyopathy in Chagas disease
Open the record for dataset details and reuse information.
Data from: Changes in cerebrospinal fluid proteins across the spectrum of untreated and treated chronic HIV-1 infection
Open the record for dataset details and reuse information.
Data from: Subsets of tissue CD4 T cells display different susceptibilities to HIV infection and death: Analysis by CyTOF and single cell RNA-seq
Open the record for dataset details and reuse information.
Data from: Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and non-injection drug users from coastal Kenya
Background: Information about HBV sero-markers, infection stages and genotypes in HIV-1 infected and uninfected injection and non-injection drug users (IDUs) in Kenya remains elusive. Methods: A cross-sectional study examining HBV sero-marker, infection stages and genotypes was conducted among HIV-1 infected and uninfected, respectively, IDUs (n = 157 and n = 214) and non-IDUs (n = 139 and n = 48), and HIV-1 uninfected non-drug using controls (n = 194) from coastal, Kenya. HBV sero-marker and infection stages were based on HBV 5-panel rapid test plasma sero-reactivity. DNA was extracted from acute and chronic plasma samples and genotypes established by nested-PCR and direct sequencing. Results: HBsAg positivity was higher in HIV-1 infected IDUs (9.6 %) relative to HIV-1 uninfected IDUs (2.3 %), HIV-1 infected non-IDUs (3.6 %), HIV-1 uninfected non-IDUs (0.0 %) and non-drug users (2.6 %; P = 0.002). Contrastingly, HBsAb positivity was higher in HIV-1 uninfected IDUs (14.6 %) and non-IDUs (16.8) in comparison to HIV-1 infected IDUs (8.3 %), and non-IDUs (8.6 %), and non-drug users (8.2 %; P = 0.023). HBcAb positivity was higher in HIV-1 infected IDUs (10.2 %) compared to HIV-1 uninfected IDUs (3.3 %), HIV-1 infected non-IDUs (6.5 %), HIV-1 uninfected non-IDUs (2.1 %) and non-drug users (4.6 %; P = 0.038). Acute (5.7 %, 1.4 %, 0.0 %, 0.0 % and 1.5 %) and chronic (5.1 %, 0.9 %, 3.6 %, 0.0 % and 1.5 %) stages were higher in HIV-1 infected IDUs, compared to HIV-1 uninfected IDUs, HIV-1 infected and uninfected non-IDUs and non-drug users, respectively. However, vaccine type response stage was higher in HIV-1 uninfected IDUs (15.4 %) relative to HIV-1 infected IDUs (6.4 %), and HIV-1 infected (6.5 %), and uninfected (10.4 %) non-IDUs, and non-drug users (5.7 %; P = 0.003). Higher resolved infection rates were also recorded in HIV-1 uninfected IDUs (11.2 %) compared to HIV-1 infected IDUs (8.3 %), and HIV-1 infected (7.2 %), uninfected (6.3 %) non-IDUs, and non-drug users (6.7 %; P = 0.479), respectively. Only A1 genotype showing minimal diversity was detected among the study participants. Conclusion: HBV sero-markers and infection staging are valuable in diagnosis and genotyping of HBV infections. Among IDUs, higher HBsAg and HBcAb positivity in HIV-1 infected and higher HBsAb positivity in HIV-1 negative IDUs suggests frequent exposure. Additionally, HBV genotype A is the dominant circulating genotype in both high and low risk populations of Kenya.
Data from: Relationship between socioeconomic status and HIV infection: findings from a survey in the Free State and Western Cape Provinces of South Africa
Background Studies have shown a mixed association between socioeconomic status [SES] and prevalent HIV infection across and within settings in sub-Saharan Africa. In general, the relationship between years of formal education and HIV infection changed from a positive to a negative association with maturity of the HIV epidemic. Our objective was to determine the association between SES and HIV in women of reproductive age in the Free State [FSP] and Western Cape Provinces [WCP] of South Africa [SA]. Study design Cross sectional Setting South Africa Methods We conducted secondary analysis on 1906 women of reproductive age from a 2007-2008 survey that evaluated effectiveness of Prevention of Mother-to-Child HIV Transmission programs. SES was measured by household wealth quintiles, years of formal education and employment status. Our analysis principally utilized logistic regression for survey data. Results There was a significant negative trend between prevalent HIV infection and wealth quintile in WCP [p-value<0.001] and FSP [p-value=0.025]. In adjusted analysis, every additional year of formal education was associated with a 10% [adjusted Odds Ratio [aOR] 0.90 [95% Confidence Interval [CI]: 0.85-0.96] significant reduction in risk of prevalent HIV infection in WCP but no significant association was observed in FSP [aOR 0.99 CI: 0.89-1.11]. There was no significant association between employment and prevalent HIV in each province: [aOR 1.54 CI: 0.84-2.84] in WCP and [aOR 0.96 CI: 0.71-1.30] in FSP. Conclusion The association between HIV infection and SES differed by province and by measure of SES and underscores the disproportionately higher burden of prevalent HIV infection among poorer and lowly educated women. Our findings suggest the need for re-evaluation of whether current HIV prevention efforts meet needs of the least educated [in WCP] and the poorest women [both WCP and FSP], and point to the need to investigate additional or tailored strategies for these women.
Data from: Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men
There is limited information on the effectiveness of available treatments for anal condyloma acuminata in HIV-1-infected men. AIM: To provide data on the effectiveness of electrosurgical excision, infrared coagulation and pharmacological (imiquimod) treatments for anal condyloma acuminata (peri-anal and/or intra-anal) in HIV-1-infected men based on authors' practice. METHODS: Single-center, retrospective descriptive analysis of HIV-1-infected men, 18 years or older treated for anal condyloma acuminata. Standard treatments were offered: electrosurgery excision, infrared coagulation and topical imiquimod. Effectiveness was evaluated by the recurrence rate at 1 year after treatment. Recurrence was defined as any anal condyloma acuminata diagnosed after 3 months of condyloma-free survival post-treatment. Anal cytology and human-papillomavirus-infection (HPV) was assessed. RESULTS: Between January 2005 and May 2009, 101 men were treated for anal condyloma acuminata: 65 (64%) with electrosurgery, 27 (27%) with infrared coagulation and 9 (9%) with imiquimod. At 1 year after treatment, the cumulative recurrence rate was 8% (4/65, 95%CI: 2-15%) with electrosurgery excision, 11% (3/27, 95%CI: 4-28%) with infrared coagulation and 11% (1/9, 95%CI: 2-44%) with imiquimod treatment. No predictive factors were associated with recurrence. Anal HPV-6 or HPV-11 was detectable in 98 (97%) patients and all had high-risk HPV genotypes, and 89 (88%) patients had abnormal anal canal cytology. Limitations: this was a retrospective descriptive analysis; limited to a single center; it cannot know if the recurrence is related to new infection. CONCLUSION. Recurrence of anal condyloma after any treatment was common. Abnormal anal cytology and high-risk HPV-infection were highly prevalent in this population, therefore at high-risk of anal cancer, and warrants careful follow-up.
Supplementary figures to Effect of bisphosphonates on vertebral fractures in HIV infected males: 7-years longitudinal study
<p>Supplementary figures to Effect of bisphosphonates on vertebral fractures in HIV infected males: 7-years longitudinal study</p>
Figure 2 in Placebo-Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 Infection
Figure 2. Self-reported risk behaviors by treatment arm and month of visit. STDs, sexually transmitted diseases.
Unravelling molecular signatures and causal factors underlying latent Cytomegalovirus infection among people living with HIV
<p>CMV seropositivity does not lead to severe <span>pathology </span>in healthy individuals, but it contributes to medical complications in people living with HIV (PLHIV). This study provides a comprehensive evaluation of how CMV <span>seropositivity</span> shapes the immune system of 1887 PLHIV, by utilizing multi-omics and deep immune phenotyping dataset<span>s</span>. We observed prominent CMV-induced signatures at the DNA methylome and transcriptome levels <span>that were </span>related to immune functions in PLHIV. High FCRL6 expression is a promising biomarker for immune activation in latent CMV infection, underlied by the demethylation of FCRL6 and up-regulation of gene expression and plasma protein concentrations in CMV<span>-seropositive</span><span> </span>PLHIV. Furthermore, the host genetics-driven elevation in both gene and protein expression of FCRL6 was associated with latent CMV infection. We also identified a significant CMV-susceptibility locus associated with cytokine production capacity and protein abundance.</p>
ART uptake and early retention among pregnant women screened HIV infected in informal health centers in Cameroon
<p><span>Informal health centers </span><span>are booming in Cameroon and are utilized by a large part of the population. Most of these IHCs have antenatal care services (ANC) and screen pregnant women for HIV. This dataset was collected in informal health centers in two cities in Cameroon: Douala and Yaounde.</span></p> <p><span>This dataset aimed at firstly, investigate the initiation of Antiretroviral therapy (ART) in pregnant women screened positive for HIV in antenatal care services of IHCs, three months after HIV screening as well as their retention at 3 months post-initiation. Secondly, study the association between this intiation and retention with type of PMTCT site or model of care ( IHCs that offered integrated ANC and ART, VS those that required referral to HIV care centers). Third, identifying associated factors to ART non-initiation in this population</span><span>.</span></p> <p>From January 2018 to July 2020, we carried out a cohort study of pregnant women attending their first ANC and screened HIV positive at IHCs in Cameroon. <span>Consenting participants were interviewed at three points: </span><span>the day of the delivery of the antenatal HIV test result, 3 months later and three months after ART initiation, using anonymous standardized questionnaires. The data collected were entered into Kobo collect and analyzed in SPSS V23.0 software.</span></p> <p>Descriptive statistics were performed. Frequencies and percentage for categorical variables; median and interquartile ranges for continuous variables. Proportions were used to calculate ART coverage and retention. Chi-square was used to compare the proportions of initiation of ART and retention between group of women screened in IHCs without ART and those screened in IHCs with ART integrated in antenatal care service. Logistic regression was used to identify factors associated to ART non-initiation at 95% confidence interval. Baseline variables were initially analyzed univariately and those which were significant at the level of 5% were retained for multivariable logistic regression. Baseline variables used for this purpose were type of PMTCT site, age group, study level, income generating activity, income generating activity of partner, relationship duration, Primiparity, Pregnancy willingness, perceived self-efficacy of being able to initiate ART.</p> <p>A total of 182 pregnant women living with HIV were enrolled in the study. At the first ANC, 91% (166/182) were naïve of ART. Among them, only 45% (74/166) initiated ART and 65% (48/74) of them were retained in ART 3 months later. PWLHIV screened in IHCs with no ART (aOR = 14.07, 95%CI: 4.68-42.32, p<0.001) and those who doubted their perceived capacity to initiate ART (aOR= 15.43, 95% CI: 4.45 to 53.44, p< 0.001) were more likely to not initiate ART</p> <p>Given the low enrollment in ART among pregnant women living with HIV, screened in informal health centers, and the early low retention among those who initiated ART, greater attention in PMTCT policies in Cameroon should be given to pregnant women screened positive for HIV during ANC in informal health centers, in order to guarantee them a continuum of PMTCT care.</p>
The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients
ClinicalTrials.gov study NCT00306410. IPD Sharing: Not stated. Countries: 1. Publications: 5.
A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment
ClinicalTrials.gov study NCT00000671. IPD Sharing: Not stated. Countries: 2. Publications: 9.
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
ClinicalTrials.gov study NCT00115609. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
ClinicalTrials.gov study NCT00004579. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand
ClinicalTrials.gov study NCT00672412. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.